Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Zosano Pharma Corp | d631900d8k.htm |
Exhibit 99.1
Zosano Pharma Reports Second Quarter 2017 Financial Results
and Operational Update
| • | John Walker appointed permanent CEO at Zosano |
FREMONT, CA, August 10, 2017—Zosano Pharma Corporation (NASDAQ:ZSAN) a clinical stage biopharmaceutical company focused on providing systemic administration of therapeutics to patients using our proprietary Adhesive Dermally-Applied Microarray (ADAM) technology, today announced financial results for the second quarter ended June 30, 2017. In addition, the Company’s Board of Directors has appointed John Walker, Zosano’s current Chairman and Interim CEO as the permanent CEO, effective immediately. Mr. Walker will also remain Chairman of the Board.
“It is with great pleasure that I accept the role of permanent CEO. I believe the company has a great deal of promise, and our lead asset, M207, has demonstrated that it can be a significant addition to the treatment options available to migraine sufferers, if approved by the FDA,” commented John P. Walker, Chairman and Chief Executive Officer. “Zosano continues to execute on its operating plan, and is progressing towards initiating our long-term safety study as previously announced. In the second quarter, we received from the U.S. Food and Drug Administration (FDA) confirmation of our previously announced study design and requirements to advance M207 towards an NDA filing. In addition, we participated in the American Headache Society meeting in Boston as a late-breaking oral presentation. We continue to prioritize increased awareness of M207 in the physician community, and plan additional conference presentations and publications in the second half of 2017.”
Recent Business Highlights and Clinical Update
| • | In June 2017, Zosano held its end of Phase 2 meetings with the FDA, where the FDA confirmed the previously announced design of the Long-term Safety Study as sufficient to support an NDA filing for M207, that the recently completed single, positive efficacy study is sufficient for NDA filing for M207, and the FDA concurred that the development strategy, which conforms to relevant regulatory guidelines, appears adequate for registration of M207. |
| • | June 2017, Zosano presented additional data from its pivotal Phase 2/3 ZOTRIP study evaluating M207 as an acute treatment for migraine during the 59th Annual Scientific Meeting of the American Headache Society in Boston, Massachusetts. The 3.8mg dose achieved significance in the secondary endpoints of pain freedom at 45 minutes and 1 hour and showed durability of effect on sustained pain freedom at 24 and 48 hours. |
| • | In July, Zosano announced the publication of positive phase 1 data of zolmitriptan delivery in Future Medicine’s Pain Management Journal |
| • | Additionally, in July we strengthened our focus on manufacturing leadership by promoting Hayley Lewis to Senior Vice President of Operations. In addition to Quality, Regulatory and FDA communications, her role has expanded to include the additional responsibility of overseeing commercial scale process development and manufacturing. |
Financial Results for the Second Quarter Ended June 30, 2017
| • | Zosano reported a net loss for the second quarter of 2017 of $6.7 million, or $0.17 per share on a basic and diluted basis, compared with a net loss of $6.6 million, or $0.54 per share on a basic and diluted basis, for the same quarter in 2016. |
| • | Research and development (R&D) expenses for the second quarter of 2017 were $4.4 million, compared with $4.3 million for the same quarter in 2016. Increased costs in the second quarter of 2017 for labor, medical affairs, and the M207 long-term safety study were largely offset by decreased costs for the M207 efficacy study upon completion of the pivotal efficacy trial. |
| • | General and administrative (G&A) expenses for the second quarter of 2017 were $2.2 million, compared with $2.0 million for the same quarter in 2016. G&A expenses for the second quarter of 2017 were up slightly, due primarily to severance costs paid to former executives. |
| • | As of June 30, 2017, we had cash and cash equivalents of $21.2 million, short-term investments in marketable securities of $7.1 million, and debt of $9.6 million. As of June 30, 2017, we had approximately 39.2 million common shares outstanding. In March, Zosano announced the completion of a public offering of common stock that generated aggregate gross proceeds of approximately $29.3 million. The financing provides funding for the continued advancement of M207 towards an NDA submission. |
About Migraine
Migraine is the leading cause of disability among neurological disorders in the United States according to the American Migraine Foundation. Migraine symptoms can include moderate to severe headache pain combined with nausea and vomiting, or abnormal sensitivity to light and sound. According to the Migraine Research Foundation, migraine affects 30 million men, women and children in the United States. Most migraines last between four and 24 hours, but some last as long as three days. According to published studies, 63% of migraine patients experience between one and four migraines per month. According to Decision Resources, prescription drug sales for migraine in the top seven countries were estimated to be $3.3 billion in 2015, and are expected to grow to $4.4 billion in 2020. Triptans, a family of tryptamine-based drugs first sold in the 1990s, account for almost 75% of anti-migraine therapies prescribed at office visits.
About M207
M207 is our proprietary formulation of zolmitriptan delivered utilizing Zosano’s proprietary Adhesive Dermally-Applied Microarray, or ADAM technology. Zosano’s ADAM technology consists of titanium microprojections coated with drug, and in the case of M207, our formulation of zolmitriptan. Our ADAM technology delivers drug by abrading the stratum corneum and allowing drug to be absorbed into the microcapillary system of the skin. In February 2017, the Company announced statistically significant results from the ZOTRIP trial, which demonstrated that the 3.8mg dose of M207 met both co-primary endpoints, achieving pain freedom and most bothersome symptom freedom at 2 hours.
About Zosano Pharma
Zosano Pharma Corporation is a clinical stage biopharmaceutical company focused on providing systemic administration of therapeutics to patients using our proprietary Adhesive Dermally-Applied Microarray, or ADAM technology. The Company recently announced positive results from our ZOTRIP study that evaluated M207, which is our proprietary formulation of zolmitriptan delivered via our ADAM technology, as an acute treatment for migraine. Zosano is focused on developing products where rapid administration of established molecules with known safety and efficacy profiles provides an increased benefit to patients, for markets where patients remain underserved by existing therapies. The Company anticipates that many of its current and future development programs may enable the Company to utilize a regulatory pathway that would streamline clinical development and accelerate the path towards commercialization. Learn more at www.zosanopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding the timing of expected clinical development milestones, sufficiency of our capital resources and need for future funding and other future events and expectations. Readers are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “might,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “goal,” “unaudited,” “approximately” or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially. These include risks and uncertainties, without limitation, associated with the process of discovering, developing and commercializing products that are safe and effective for use as human therapeutics, risks inherent in the effort to build a business around such products and other risks and uncertainties described under the heading “Risk Factors” in the Company’s most recent annual report on Form 10-K. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot in any way guarantee that the future results, level of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. All forward-looking statements are based on information currently available to Zosano and Zosano assumes no obligation to update any such forward-looking statements.
Zosano Contact:
Georgia Erbez
Chief Business Officer and
Chief Financial Officer
510-745-1200
Investor Contact:
Jamien Jones
Blueprint Life Science Group
415-375-3340 x 5
jjones@bplifescience.com
ZOSANO PHARMA CORPORATION AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited; in thousands, except per share amounts)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||||
| Revenue | $ | — | $ | — | $ | — | $ | — | ||||||||
| Operating expenses: |
||||||||||||||||
| Research and development |
4,363 | 4,298 | 8,989 | 9,920 | ||||||||||||
| General and administrative |
2,188 | 1,951 | 4,310 | 4,127 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total operating expenses |
6,551 | 6,249 | 13,299 | 14,047 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Loss from operations | (6,551 | ) | (6,249 | ) | (13,299 | ) | (14,047 | ) | ||||||||
| Other income (expense): |
||||||||||||||||
| Interest expense, net |
(207 | ) | (321 | ) | (454 | ) | (637 | ) | ||||||||
| Other income, net |
12 | 50 | 10 | 49 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss | $ | (6,746 | ) | $ | (6,520 | ) | $ | (13,743 | ) | $ | (14,635 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss per common share – basic and diluted | $ | (0.17 | ) | $ | (0.54 | ) | $ | (0.46 | ) | $ | (1.22 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Weighted-average shares used in computing net loss per common share – basic and diluted | 39,200 | 12,012 | 29,820 | 11,989 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
ZOSANO PHARMA CORPORATION AND SUBSIDIARY
SELECTED CONDENSED CONSOLIDATED BALANCE SHEETS DATA
(in thousands)
| June 30, 2017 |
December 31, 2016 |
|||||||
| (unaudited) | ||||||||
| Cash, cash equivalents and marketable securities |
$ | 28,225 | $ | 15,003 | ||||
| Total current assets |
29,391 | 15,276 | ||||||
| Total assets |
34,644 | 20,906 | ||||||
| Secured promissory note |
9,634 | 12,542 | ||||||
| Total liabilities |
12,687 | 16,421 | ||||||
| Stockholders’ equity |
21,957 | 4,485 | ||||||
# # #